7636 related articles for article (PubMed ID: 22987943)
1. Advances and perspectives in immunotherapy of melanoma.
Schadendorf D; Vaubel J; Livingstone E; Zimmer L
Ann Oncol; 2012 Sep; 23 Suppl 10():x104-8. PubMed ID: 22987943
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
Eggermont AM
Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of melanoma: present options and future promises.
Rotte A; Bhandaru M; Zhou Y; McElwee KJ
Cancer Metastasis Rev; 2015 Mar; 34(1):115-28. PubMed ID: 25589384
[TBL] [Abstract][Full Text] [Related]
4. [Immunotherapy of melanomas].
Zimmer L; Vaubel J; Schadendorf D
Hautarzt; 2012 Dec; 63(12):952-8. PubMed ID: 23097082
[TBL] [Abstract][Full Text] [Related]
5. Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.
Quirk SK; Shure AK; Agrawal DK
Transl Res; 2015 Nov; 166(5):412-24. PubMed ID: 26118951
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant ipilimumab in stage III melanoma: New landscape, new questions.
Eggermont AM
Eur J Cancer; 2016 Dec; 69():39-42. PubMed ID: 27816830
[TBL] [Abstract][Full Text] [Related]
7. Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma.
van Akkooi AC; Atkins MB; Agarwala SS; Lorigan P
Am Soc Clin Oncol Educ Book; 2016; 35():e505-14. PubMed ID: 27249760
[TBL] [Abstract][Full Text] [Related]
8. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).
Weber J
Oncologist; 2008; 13 Suppl 4():16-25. PubMed ID: 19001147
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
10. Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies.
Ascierto PA
Tumori; 2013; 99(6):302e-5e. PubMed ID: 24503809
[TBL] [Abstract][Full Text] [Related]
11. The role of adjuvant therapy in melanoma management.
Barth A; Morton DL
Cancer; 1995 Jan; 75(2 Suppl):726-34. PubMed ID: 7805001
[TBL] [Abstract][Full Text] [Related]
12. [Advances in immunotherapy for metastatic melanoma].
Oláh J
Magy Onkol; 2017 Jun; 61(2):132-136. PubMed ID: 28585614
[TBL] [Abstract][Full Text] [Related]
13. New drugs in melanoma: it's a whole new world.
Eggermont AM; Robert C
Eur J Cancer; 2011 Sep; 47(14):2150-7. PubMed ID: 21802280
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
Eggermont AM; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Konto C; Hoos A; de Pril V; Gurunath RK; de Schaetzen G; Suciu S; Testori A
Lancet Oncol; 2015 May; 16(5):522-30. PubMed ID: 25840693
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapies in the treatment of stage II and III malignant melanoma.
Kavanagh D; Hill AD; Djikstra B; Kennelly R; McDermott EM; O'Higgins NJ
Surgeon; 2005 Aug; 3(4):245-56. PubMed ID: 16121769
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for the management of advanced melanoma: the next steps.
Zikich D; Schachter J; Besser MJ
Am J Clin Dermatol; 2013 Aug; 14(4):261-72. PubMed ID: 23516145
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting.
Herrscher H; Robert C
Curr Opin Oncol; 2020 Mar; 32(2):106-113. PubMed ID: 31876547
[TBL] [Abstract][Full Text] [Related]
18. The impact of the immunotherapy revolution on lymph nodal surgery.
Eggermont AMM
Bull Cancer; 2020 Jun; 107(6):640-641. PubMed ID: 31610910
[No Abstract] [Full Text] [Related]
19. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
Eggermont AMM; Dummer R
Eur J Cancer; 2017 Nov; 86():101-105. PubMed ID: 28968566
[TBL] [Abstract][Full Text] [Related]
20. Advances in immunotherapy for melanoma.
Redman JM; Gibney GT; Atkins MB
BMC Med; 2016 Feb; 14():20. PubMed ID: 26850630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
